Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
InsmedInsmed(US:INSM) Prnewswire·2026-01-09 20:00

®— BRINSUPRI (brensocatib) Unaudited Total Revenues of Approximately 144.6MillionforFirstFullQuarterofLaunch;Approximately144.6 Million for First Full Quarter of Launch; Approximately 172.7 Million for Full-Year 2025— ®—ARIKAYCE (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately 433.8Million——Full−Year2026GlobalARIKAYCERevenuesExpectedtobeBetween433.8 Million— —Full-Year 2026 Global ARIKAYCE Revenues Expected to be Between 450 Million and $470 Million— —Topline Data from Phase 3 ENCORE Study of ARIKAYCE in Patients with Newly ...